Enhertu granted Priority Review in the US for patients with HER2-low metastatic breast cancer
25 July 2022 07:00 BST Enhertu granted Priority Review in the US for patients with HER2-low metastatic breast cancer Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo's Enhertu is the first HER2-directed therapy to demonstrate a survival benefit in this population Application being evaluated under FDA Real-Time Oncology Review and Project Orbis AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for the treatment of adult patients in the